Quantcast

Latest Idiopathic thrombocytopenic purpura Stories

2009-01-20 07:30:00

SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chinese State Food and Drug Administration (SFDA) for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) in China. If the extension is approved, 3SBio expects...

2008-12-08 13:00:00

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a chronic and serious autoimmune disorder characterized by lower than expected platelet counts in the blood, sometimes leading to serious bleeding events. The results were presented today as an...

2008-12-06 11:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, will be presented in a press conference on Saturday, December 6, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. The studies featured in the press conference will...

2008-12-06 10:00:00

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies. Patients receiving PROMACTA were eight times more likely than those on placebo to maintain platelet counts between 50,000 to...

2008-11-03 18:00:20

Protalex, Inc. (OTCBB:PRTX) today announced that Steven H. Kane, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 3:40 p.m. Eastern Time. The event will be held from November 10-12, 2008 at the New York Palace Hotel in New York. Individuals may listen to a live webcast of the presentation by logging on to the Investors section of Protalex' web site, www.protalex.net, a few minutes...

2008-10-28 15:00:29

New funding is available for nurses seeking to improve treatment of patients with auto-immune diseases and cancer, through a series of grants being awarded by the DAISY Foundation. Applications are now being accepted for the foundation's J. Patrick Barnes Research Grant, which funds nursing research and evidence-based practice projects. Two types of grants will be awarded: large grants of up to $5,000 for projects that can be completed within two years and small grants of up to $1,000 for...

2008-10-22 18:00:09

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif(R) (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab...

2008-10-15 12:00:33

Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage. Gamunex is an immunoglobulin intravenous (IGIV) therapy that contains antibodies purified from the donated blood plasma of thousands of people. Gamunex is indicated as replacement therapy of primary humoral...

2008-08-25 12:01:19

Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura. According to the company, Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic disease. The FDA approval of Nplate was based on efficacy and safety...

2008-08-25 09:00:26

The U.S. Food and Drug Administration says it has approved Nplate (romiplostim), the first product that directly stimulates bone marrow platelet production. The FDA said the new drug will be used to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding. The condition, which usually develops in adults, is known as chronic immune thrombocytopenic purpura, or ITP, a disease that results in a low number of platelets, the blood components that help...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related